Cadrenal Therapeutics financials
$1.08−0.92%
Close Sep 30, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — |
| Operating income | -$13.5M | -$11.0M | -$7.6M |
| Net income | -$13.2M | -$10.7M | -$8.4M |
| Net margin | — | — | — |
| Diluted EPS | $-6.64 | $-8.73 | $-9.29 |
| EBITDA | -$13.5M | -$11.0M | -$7.6M |
| Operating cash flow | -$12.6M | -$7.4M | -$3.5M |
| Free cash flow | -$12.6M | -$7.4M | -$3.5M |
| Diluted shares | 2.0M | 1.2M | 0.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $4.0M | $10.0M | $8.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 |
| Total assets | $4.3M | $10.1M | $8.5M |
| Total liabilities | $1.6M | $2.7M | $826.9K |
| Shareholders' equity | $2.7M | $7.4M | $7.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology